Orris

Free Light chain

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Here is a comprehensive overview of Immunoglobulin Free Light Chains (FLC) drawn from the textbooks:

Immunoglobulin Free Light Chains (FLC)

What Are They?

Free light chains (FLCs) are κ (kappa) and λ (lambda) immunoglobulin light chains that are not bound to heavy chains (i.e., not part of an intact immunoglobulin molecule). Under normal physiology:
  • Light chains are synthesized in slight excess of heavy chains
  • They are rapidly cleared by the kidneys within a few hours
  • Thus, they do not accumulate in blood
In plasma cell disorders, light-chain synthesis can greatly exceed heavy-chain production, releasing variable quantities of FLCs into blood and urine.
— Henry's Clinical Diagnosis and Management by Laboratory Methods

The FLC Assay — Principle

Standard anti-light chain antibodies (used in immunofixation electrophoresis / IFE) react with light chains whether bound to heavy chains or free. The FLC-specific assay uses antibodies that react with epitopes normally hidden when light chains are bound to heavy chains — exposing them only when the light chain is free.
This gives quantitative information complementary to:
  • Protein electrophoresis (PEL)
  • Immunofixation electrophoresis (IFE)
  • Quantitative immunoglobulin measurement
A key advantage: the assay is automated.

Interpretation

MeasurementSignificance
κ FLCQuantified separately
λ FLCQuantified separately
κ/λ ratio (rFLC)Normal: 0.26 – 1.65
Elevated ratio (high κ)κ monoclonal light-chain proliferation
Low ratio (high λ)λ monoclonal light-chain proliferation
In renal disease, both κ and λ may be elevated due to impaired clearance — the ratio helps correct for this and remains interpretable.

Clinical Applications (IMWG Consensus Guidelines)

  1. Screening for plasma cell disorders
    • Serum FLC + serum PEL + IFE is sufficient to screen for most plasma cell disorders
    • Exception: AL (light-chain) amyloidosis — 24-hour urine IFE remains essential
    • The FLC assay can replace 24-hour urine IFE for all plasma cell disorders except AL amyloidosis
  2. Prognostication at diagnosis — recommended for:
    • MGUS
    • Smoldering or active multiple myeloma
    • Solitary plasmacytoma
    • AL amyloidosis
    • Baseline FLC values predict progression risk
  3. Monitoring treatment response — routine serial use is recommended in:
    • Oligosecretory multiple myeloma
    • AL amyloidosis
    • Also used to determine stringent complete response (sCR) in patients achieving CR
  4. Biomarker for malignancy diagnosis — an involved FLC ≥100 mg/L is a threshold used to diagnose multiple myeloma even without other conventional indicators (IMWG update).

Role in Specific Diseases

ConditionRelevance of FLC
MGUSAbnormal FLC ratio is a risk factor for progression to myeloma; used in risk stratification
Multiple myelomaElevated involved FLC; monitoring during/after therapy
AL amyloidosisDifference between involved and uninvolved FLC (<50 mg/L = low burden, better prognosis)
Light-chain MGUSNo intact M-protein detectable by electrophoresis; FLC assay is the key diagnostic test
Oligosecretory myelomaLittle or no intact M-protein; FLC is the primary quantitative marker
— Goldman-Cecil Medicine, Henry's Clinical Diagnosis and Management by Laboratory Methods

FLC vs. Urine Bence Jones Protein

Historically, Bence Jones protein (BJP) in urine was used to detect free light chains. The serum FLC assay is:
  • More sensitive than electrophoresis or immunofixation for detecting free monoclonal light chains
  • Avoids the need for inconvenient 24-hour urine collections (except in AL amyloidosis)
  • More rapidly responsive to changes in plasma cell mass

Key Reference Values

ParameterNormal Range
κ/λ FLC ratio0.26 – 1.65
Involved FLC threshold for myeloma diagnosis≥ 100 mg/L
dFLC (difference between involved & uninvolved) threshold (AL amyloidosis prognosis)< 50 mg/L = low burden
This is a shared conversation. Sign in to Orris to start your own chat.